title: cC1qR/CR and gC1qR/p33: observations in cancer.
abstract: The survival and growth of a primary tumor depends, by and large, on three major events: immune evasion, angiogenesis and metastasis. Tumor cells are "modified self", and as such express a plethora of modified surface antigens capable of inducing antibody production. Anti-tumor cell antibodies should, in theory, activate complement resulting in cell destruction. But this is not the case. Akin to many pathogenic microorganisms whose survival depends on evading the immune system, cancer cells have also evolved diverse mechanisms to prevent host mediated cell destruction by either retaining critical regulatory molecules or by hijacking host proteins to ensure their survival. Although immune evasion, angiogenesis and metastasis are complex biological processes involving a myriad of tumor associated proteins, enzymes, and cytokines, C1qRs can, nonetheless play an important role in all or part of these processes. Although both cC1qR/CR and gC1qR are expressed by all somatic cells, with the exception of red blood cells, both are highly upregulated on almost all types of tumors. It is not surprising therefore that blockade of C1qR on tumor cells inhibits their proliferation suggesting the significance of C1qRs in tumor growth and progression. Interestingly, the two C1q receptors: cC1qR/CR and gC1qR play a differential role in carcinogenesis. While gC1qR promotes tumor cell survival by enhancing angiogenesis and metastasis and also by contributing to the hypercoagulable and prothrombotic microenvironment, cC1qR/CR expression represents a pro-phagocytic "eat-me" signal through which cC1qR/CR expressing tumor cells are tagged for destruction by macrophages. The data accumulated to date therefore identify gC1qR and cC1qR/CR as potential targets for the design of either protein-based, antibody-based or chemical based therapeutic intervention that could be used to enhance conventional anti-cancer therapy. The inhibition of tumor cell proliferation by monoclonal antibody recognizing the C1q site on gC1qR, as well as the identification of agents such as anthracyclin that enhance cC1qR/CR expression on tumor cells, are indeed steps in the right direction.
authors.affiliation: The Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, and Pathology, Weill-Cornell Medical College, New York, NY 10065, United States. Electronic address: peersche@mskcc.org.
authors.forename: Ellinor I B
authors.initials: EI
authors.lastname: Peerschke
authors.affiliation: The Departments of Medicine and Pathology, Stony Brook University, Stony Brook, NY 11794-8161, United States.
authors.forename: Berhane
authors.initials: B
authors.lastname: Ghebrehiwet
mesh_terms: D000818:Animals; D037282:Calreticulin / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D002352:Carrier Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D015922:Complement C1q / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D006801:Humans; D024101:Mitochondrial Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D009369:Neoplasms / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*
chemical_list: C087299:C1QBP protein, human; D037282:Calreticulin; D002352:Carrier Proteins; D024101:Mitochondrial Proteins; D015922:Complement C1q
keywords: C1q receptors; C1qR and cancer; Cancer, cC1qR and gC1qR